Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • State of the Art Mini Review
  • Published:

Acute Leukemia Forum 2000, Advances and Controversies in the Therapy of Acute Myelogenous Leukemia

Marrow vs peripheral blood: impact on transplant outcome

Leukemia volume 15, pages 686–687 (2001)Cite this article

Mobilized peripheral blood has almost completely replaced marrow as a source of hematopoietic stem cells for autologous transplantation. The faster hematopoietic recovery that results from use of this product has contributed to the decrease in the morbidity and mortality of transplant and has led to a wider use of the therapy, including treatment of older patients. Because of these encouraging results, phase II studies were initiated to explore the feasibility of using allogeneic peripheral blood stem cells (PBSC) instead of marrow in the allogeneic stem cell transplantation setting.12 Most studies to date have shown faster neutrophil and platelet recovery, mimicking the data obtained in autologous transplant studies.

One major concern of this approach was the possibility of increasing the incidence of acute graft-versus-host disease (GVHD) due to the infusion of a large number of T cells with the peripheral blood stem cell product. To the surprise of many investigators, the use of PBSC does not appear to increase the rate of severe acute GVHD compared to marrow, although most studies do suggest that the incidence of chronic GVHD is increased.123

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD . Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-simulating factor Blood 1995 85: 1655–1658

    CAS  PubMed  Google Scholar 

  2. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB . Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts Blood 1995 85: 1659–1665

    CAS  PubMed  Google Scholar 

  3. Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, DiPersio JF . Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality J Clin Oncol 1999 17: 806–812

    Article  CAS  Google Scholar 

  4. Bensinger WI, Martin P, Storer B, Clift R, Forman S, Negrin R . A prospective, randomized trial of transplantation of marrow versus peripheral blood cells from HLA-identical siblings in patients treated for hematologic malignancies New Engl J Med 2001 344: 175–181

    Article  CAS  Google Scholar 

  5. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL, Mills KC, Thomas ML, Pirruccello SJ, Letheby BA, Arneson MA, Jackson JD . Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation Bone Marrow Transplant 1996 17: 101–109

    CAS  PubMed  Google Scholar 

  6. Mielcarek M, Roecklein BA, Torok-Storb B . CD14+ cells in granulocyte colony-stimulating factor (GCSF)-mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma Blood 1996 87: 574–580

    CAS  PubMed  Google Scholar 

  7. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C . Granulocyte colony-stimulating factor mobilizes T helper 2-inducing dendritic cells Blood 2000 95: 2484–2490

    CAS  PubMed  Google Scholar 

  8. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW . The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow Blood 1999 94: 384–389

    CAS  PubMed  Google Scholar 

  9. Appelbaum FR . Choosing the source of stem cells for allogeneic transplantation: no longer a peripheral issue Blood 1999 94: 381–383

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. City of Hope National Medical Center, Duarte, CA, USA

    SJ Forman

Authors
  1. SJ Forman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forman, S. Marrow vs peripheral blood: impact on transplant outcome. Leukemia 15, 686–687 (2001). https://doi.org/10.1038/sj.leu.2402086

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402086

Search

Advanced search

Quick links